Manufacturing scale-up/scale-out and automation

CELL AND GENE THERAPY INSIGHTS

September 2026

Manufacturing scale-up/scale-out and automation

Download PDF

Expert Insight

Education and training for the cell and gene therapy sector: initiatives, gaps and future opportunities

Education and training for the cell and gene therapy sector: initiatives, gaps and future opportunities

Gary Gilleskie, Elissa Hudspeth

ATMP development and market access in Europe and the United States: why scientific innovation alone no longer wins

ATMP development and market access in Europe and the United States: why scientific innovation alone no longer wins

Jens Kurth , Günter Harms

Review

Hidden translation costs in cell and gene therapy manufacturing

Hidden translation costs in cell and gene therapy manufacturing

Robert E Nordon

Innovator Insight

Evaluation of ice recrystallization inhibitors for preserving the post-thaw function of iPSC-derived natural killer cells

Evaluation of ice recrystallization inhibitors for preserving the post-thaw function of iPSC-derived natural killer cells

Anna Jezierski, Robert N Ben

Scale-up and process transfer considerations in lentiviral vector manufacturing

Scale-up and process transfer considerations in lentiviral vector manufacturing

Jonathan Zmuda, Shin Kawamata

Infographic

End-to-end CAR-T manufacturing workflow

End-to-end CAR-T manufacturing workflow

Cell processing in cell therapy manufacturing

Cell processing in cell therapy manufacturing

Accelerating AAV biosafety and characterization decisions with validated NGS workflows

Accelerating AAV biosafety and characterization decisions with validated NGS workflows

Andrew Hillhouse

Interview

Building an autologous CAR-T manufacturing network from scratch: infrastructure, workforce, and what comes next

Building an autologous CAR-T manufacturing network from scratch: infrastructure, workforce, and what comes next

Frederik Buysse

From feasibility to access: how is cell therapy’s central challenge evolving?

From feasibility to access: how is cell therapy’s central challenge evolving?

Christian Chabannon

Tech Showcase

Rapid, simple purification of AAV using low-speed centrifugation

Rapid, simple purification of AAV using low-speed centrifugation

Michael Dzuricky

Webinars

Cell-derived nanoparticles: a new paradigm for CAR-T cell activation and manufacturing

Cell-derived nanoparticles: a new paradigm for CAR-T cell activation and manufacturing

P Moura, B Shy, K Li et al.

Transitioning to serum-free T cell manufacturing: process considerations and cross-platform scale-up data

Transitioning to serum-free T cell manufacturing: process considerations and cross-platform scale-up data

Chengkang Zhang, PhD

From pleural T cells to patients: translating FastTIL research into first-in-human cell therapy

From pleural T cells to patients: translating FastTIL research into first-in-human cell therapy

Albert Donnenberg, PhD

From research to clinical manufacturing: advancing gene-edited HSC therapies through collaboration

From research to clinical manufacturing: advancing gene-edited HSC therapies through collaboration

S Cherqui, PhD, D S Kaufman, PhD, N Ravinder, PhD